Cardiff University researchers examined prior aspirin and cancer studies and reported their findings in the journal Open Biology.
According to study, there may be advantages to using aspirin over other painkillers that outweigh the disadvantages. They discussed the molecular factors that would account for the impact and discovered concrete proof that patients who took aspirin lived longer.
According to the experts, a number of studies indicate that aspirin may increase survival rates for certain malignancies by roughly 20%. A third less cancer has been reported to spread, according to certain research.
These include “reductions by aspirin in cancer-related inflammation, abnormal clotting and abnormal blood vessel growth, and enhancement in cellular repair,” said the team.
However, they emphasised the need for more proof because the outcomes of many trials were inconsistent. According to researchers, an amazing synchronisation exists between aspirin’s biological effects on cancer-related processes and its impacts on clinical outcomes in cancer.
According to the findings, aspirin is a generally safe medication, particularly for cancer patients.
Sam Godfrey, head of research information at Cancer Research UK said: “This review examines what we know so far about the fascinating effect that aspirin has on the biology of cancer and how it might be helping to increase survival and prevent cancer from spreading to other parts of the body. But we still need more clinical research to establish how effective aspirin is, what patients will benefit from taking the drug and how much they should take and for how long.”
The largest clinical experiment ever conducted to determine if aspirin can stop certain types of cancer from returning is called Add-Aspirin, and it is being funded by Cancer Research UK to help address some of these questions.
To determine whether regular aspirin use can stave off recurrence or mortality, the patients would have undergone treatment for early-stage cancer.
It’s anticipated that 11,000 patients from the UK, Ireland, and India would take part in the new trial.
Parvathy Sukumaran 
